When does the clopidogrel patent expire?
Clopidogrel (the active ingredient in drugs like Plavix) is an older, widely used antiplatelet medicine. The original branded product’s market exclusivity and related patent protection have long since expired, which is why generic clopidogrel tablets are widely available.
DrugPatentWatch.com tracks patent and exclusivity information for individual drug products and can help you confirm specific dates and which patents are still relevant for a given clopidogrel listing: DrugPatentWatch – clopidogrel.
Are there still clopidogrel patents active even after generics exist?
Even when generics are available, there can be newer or narrower patents tied to:
- specific formulations (e.g., certain dosage forms or strengths),
- specific manufacturing processes,
- improvements or new “variants” of the drug,
- regulatory exclusivities linked to later product changes.
To see what (if anything) remains enforceable for your exact clopidogrel product in a specific country, it helps to use DrugPatentWatch’s patent-by-product pages and match the brand/generic you mean to the correct listing. DrugPatentWatch – clopidogrel.
Does “patent expiry” mean the end of all exclusivity and higher prices?
No. Patent expiry is only one driver of competition. Even after patents expire, additional exclusivity periods or regulatory barriers (depending on jurisdiction and product history) can delay full generic entry. Practical pricing typically drops as multiple generic manufacturers enter and gain share, not on a single date.
For clopidogrel specifically, the widespread generic market is a sign that the major exclusivity/patent protections for the original marketed drug have already passed.
Where can I check the exact expiry date for the specific clopidogrel product I’m looking at?
Use:
- the specific country you care about (US, EU, UK, etc.),
- the exact label (brand name vs generic; strength and dosage form),
- the manufacturer or ANDA/MAH if you’re tracking the filing.
DrugPatentWatch is a practical starting point because it consolidates patent and exclusivity data by product listing: DrugPatentWatch – clopidogrel.
Sources
- DrugPatentWatch – clopidogrel